Oncology News | pharmaphorum

News

Joy as NICE lifts restrictions on myeloma drug Elrexfio

Patients in England and Wales with multiple myeloma are celebrating a decision by NICE to relax strict restrictions on eligibility to receive Pfizer's Elrexfio.

News

vaccine vial held by hands in surgical green gloves

MSD, Moderna start phase 3 adjuvant lung cancer trial

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-sta

News

MSD buys Modifi for $1.3bn to boost oncology pipeline

MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics for difficult-to-treat brain tumours, including glioblastomas.

News

FDA clears Astellas' Vyloy as first claudin 18.2 cancer drug

At its second attempt, Astellas has won FDA approval for its first-in-class cancer therapy, Vyloy, which got the green light for certain gastric cancers.

News

Foundation stone ceremony at Orano Med's ATLab plant in France, set to be the first industrial-scale pharma facility in Europe for lead-212 isotopes

Sanofi invests €300m in Orano Med's lead-based radioligands

Sanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclea

News

NICE backs first targeted therapy for ALK+ lung cancer

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.

Joy as NICE lifts restrictions on myeloma drug Elrexfio

MSD, Moderna start phase 3 adjuvant lung cancer trial

MSD buys Modifi for $1.3bn to boost oncology pipeline

FDA clears Astellas' Vyloy as first claudin 18.2 cancer drug

Sanofi invests €300m in Orano Med's lead-based radioligands

NICE backs first targeted therapy for ALK+ lung cancer

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks